What is William Blair's Estimate for RARE FY2025 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Stock analysts at William Blair decreased their FY2025 earnings estimates for Ultragenyx Pharmaceutical in a research report issued to clients and investors on Monday, July 14th. William Blair analyst S. Corwin now anticipates that the biopharmaceutical company will earn ($5.36) per share for the year, down from their prior estimate of ($3.48). William Blair currently has a "Outperform" rating and a $65.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. William Blair also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($1.17) EPS, Q1 2026 earnings at ($1.33) EPS, Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at $0.46 EPS and FY2026 earnings at ($0.85) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The firm had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The firm's revenue for the quarter was up 28.0% compared to the same quarter last year. During the same period last year, the business earned ($2.03) earnings per share.

RARE has been the subject of a number of other research reports. Wedbush cut their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday. Guggenheim restated a "buy" rating and issued a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Wells Fargo & Company dropped their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, July 10th. Morgan Stanley decreased their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday. Finally, JPMorgan Chase & Co. lifted their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average target price of $83.64.

Ultragenyx Pharmaceutical Price Performance

RARE stock traded up $0.33 during trading hours on Wednesday, reaching $27.64. 1,408,774 shares of the stock were exchanged, compared to its average volume of 959,064. Ultragenyx Pharmaceutical has a 12 month low of $26.85 and a 12 month high of $60.37. The company has a market cap of $2.61 billion, a price-to-earnings ratio of -4.71 and a beta of 0.26. The firm's 50-day moving average is $36.00 and its 200-day moving average is $38.46.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 669 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $35,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter worth $57,000. Finally, Headlands Technologies LLC bought a new position in Ultragenyx Pharmaceutical in the first quarter valued at $59,000. 97.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the sale, the director owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders have sold 3,167 shares of company stock valued at $118,824. 5.50% of the stock is currently owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.